LMX1A and colorectal carcinoma: However, we found that early-stage (stage I or II) CRC patients with LMX1A methylation exhibited a poorer 5-year overall survival (p = 0.0108) and disease-free survival (p = 0.0468) than those without LMX1A methylation (Figure 2B).